Oncology and Hematology - Prova Education

113-128 of 226

Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Hussein Tawbi, MD, PhD; Sapna Patel, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Sapna Patel, MD; John M. Kirkwood, MD
1.00 program credit
- Sapna Patel, MD
- John M. Kirkwood, MD
1.00 program credit
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD; Sapna Patel, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
CME/CE
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD; Elizabeth R. Plimack, MD, MS, FASCO
0.25 credits
- Robert J. Motzer, MD
- Elizabeth R. Plimack, MD, MS, FASCO
0.25 credits
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS; Komal Jhaveri, MD, FACP
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CME/CE
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS; Sarah Psutka, MD, MS
0.25 credits
- Neal Shore, MD, FACS
- Sarah Psutka, MD, MS
0.25 credits
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
CME/CE
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
Aditya Bardia, MD, MPH, FASCO; Tiffany Traina, MD
0.25 credits
- Aditya Bardia, MD, MPH, FASCO
- Tiffany Traina, MD
0.25 credits
MinuteCE®
Optimizing Ovarian Function Suppression in Hormone Receptor-Positive Breast Cancer: Best Practices for the Community Clinician
Sandra Swain, MD; Virginia Kaklamani, MD
0.50 credits 4 episodes
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 credits 4 episodes
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD; Virginia Kaklamani, MD
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD; Virginia Kaklamani, MD
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD; Virginia Kaklamani, MD
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits

Previous
1
2
…
6
7
8
9
10
…
14
15
Next

8/11